FLT3 amplification

Our study demonstrated that amplicon-based NGS assays can be routinely applied to clinical samples to detect amplification. However, they are not sufficiently sensitive in detecting amplification when tumor celluarity is less than 30%, which is a major limitation that should be clearly stated in NGS reporting.

HTS is a useful approach that allows simultaneously analyzing mutations, CNVs and the clonal repertoire in T-ALL patients. This approach may simplify the genetic assessment of ALL.

This case study reports a rare double minute chromosome via FLT3 amplification in CMML by using array-based comparative genomic hybridization and fluorescence in situ hybridization analyses. The study also proposed another possible mechanism of FLT3 genes in leukemogenesis.

Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications...Further investigations of FLT3 amplification as a potential treatment target in mCRC are warranted. SUPPORTING INFORMATION.

Monotherapy with sunitinib does not have clinical activity in patients with mCRC with FLT-3 amplification and should not be prescribed for off-label use. Other treatments should be considered for these patients, including treatments offered in clinical trials.